Tags

Type your tag names separated by a space and hit enter

[Bismuth preparations in the treatment of patients with gastric and duodenal ulcer disease].
Klin Med (Mosk). 2008; 86(9):57-63.KM

Abstract

Studies of the role of H. pylori (Hp) in etiopathogenesis of a number of common diseases of the upper gastrointestinal tract changed traditional approaches to their management with emphasis on antibiotic therapy. Positive effect of Hp eradication was confirmed in numerous randomized clinical studies. Bismuth-containing drugs have been used for a long time to treat gastrointestinal disorders. To-day, bismuth tri-potassium di-citrate (de---nol) is considered to be an optimal tool for different schemes of eradication therapy (triple and quadruple therapy of the first and second lines) and recommended to improve its efficiency by overcoming resistance of Hp to antibiotics. The overall efficacy of anti-helicobacterial therapy using bismuth tri-potassium di-citrate amounts to 81-98%. This compound has cytoprotective effect on gastric and duodenal mucosa, besides antibacterial action. All these properties characterize de-nol as a single universal preparation for the treatment of erosive ulcers in the gastrointestinal tract.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Review

Language

rus

PubMed ID

19048841

Citation

Maev, I V., et al. "[Bismuth Preparations in the Treatment of Patients With Gastric and Duodenal Ulcer Disease]." Klinicheskaia Meditsina, vol. 86, no. 9, 2008, pp. 57-63.
Maev IV, Samsonov AA, Golubev NN. [Bismuth preparations in the treatment of patients with gastric and duodenal ulcer disease]. Klin Med (Mosk). 2008;86(9):57-63.
Maev, I. V., Samsonov, A. A., & Golubev, N. N. (2008). [Bismuth preparations in the treatment of patients with gastric and duodenal ulcer disease]. Klinicheskaia Meditsina, 86(9), 57-63.
Maev IV, Samsonov AA, Golubev NN. [Bismuth Preparations in the Treatment of Patients With Gastric and Duodenal Ulcer Disease]. Klin Med (Mosk). 2008;86(9):57-63. PubMed PMID: 19048841.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Bismuth preparations in the treatment of patients with gastric and duodenal ulcer disease]. AU - Maev,I V, AU - Samsonov,A A, AU - Golubev,N N, PY - 2008/12/4/pubmed PY - 2008/12/31/medline PY - 2008/12/4/entrez SP - 57 EP - 63 JF - Klinicheskaia meditsina JO - Klin Med (Mosk) VL - 86 IS - 9 N2 - Studies of the role of H. pylori (Hp) in etiopathogenesis of a number of common diseases of the upper gastrointestinal tract changed traditional approaches to their management with emphasis on antibiotic therapy. Positive effect of Hp eradication was confirmed in numerous randomized clinical studies. Bismuth-containing drugs have been used for a long time to treat gastrointestinal disorders. To-day, bismuth tri-potassium di-citrate (de---nol) is considered to be an optimal tool for different schemes of eradication therapy (triple and quadruple therapy of the first and second lines) and recommended to improve its efficiency by overcoming resistance of Hp to antibiotics. The overall efficacy of anti-helicobacterial therapy using bismuth tri-potassium di-citrate amounts to 81-98%. This compound has cytoprotective effect on gastric and duodenal mucosa, besides antibacterial action. All these properties characterize de-nol as a single universal preparation for the treatment of erosive ulcers in the gastrointestinal tract. SN - 0023-2149 UR - https://www.unboundmedicine.com/medline/citation/19048841/[Bismuth_preparations_in_the_treatment_of_patients_with_gastric_and_duodenal_ulcer_disease]_ L2 - https://antibodies.cancer.gov/detail/CPTC-DLC1-1 DB - PRIME DP - Unbound Medicine ER -